Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk
AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.
You may also be interested in...
US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.